GlaxoSmithKline restless legs drug to run short on CMO issues; Baxter sees Q1 earnings drop on buyout costs;

@FiercePharma: Baxter to put $300M into old Genmab plant in Minnesota. More | Follow @FiercePharma

@EricPFierce: Is your company among the top 10 pharma companies by employees? If so, where does it fall? Story | Follow @EricPFierce

> Production problems at a contract manufacturer will put GlaxoSmithKline's ($GSK) restless legs drug Horizant in short supply till June. Report

> Baxter International's ($BAX) first-quarter earnings dropped on acquisition costs to $552 million, as its pharma-partnering sales suffered. Release | Report

> South Africa's Aspen Pharmacare plans to buy Nestle's nutrition business in the country for $215 million. Report

> Elan ($ELN) bought back $1 billion of its shares at $11.25 each, automatically depressing Royalty Pharma's $7.3 billion takeover offer. Report

> The GAVI Alliance made a deal with India's Biological E to supply a pentavalent childhood vaccine at a price of $1.19 per dose, almost $1-per-shot lower than the weighted average price last year. Report

Medical Device News

@FierceMedDev: Combat Medical Systems wins $86M govt. contract. Story | Follow @FierceMedDev

@MarkHFierce: Dx development for the developing world is a hot new area, and the U.K.'s Lumora is diving in. More | Follow @MarkHFierce

 @DamianFierce:  Abbott won FDA approval for a new eye implant, part of its efforts to boost sluggish medical device sales. News | Follow @DamianFierce

> EU faulty implant trial gets colorful amid patients' jeers. Story

> Illumina reaches into China with diagnostics partnership. Item

> Baxter infusion pump, dialysis sales rise slowly. More

Biotech News

@FierceBiotech: GlaxoSmithKline picks up FDA panel plug for Breo approval. Story | Follow @FierceBiotech

@RyanMFierce: S. Korean biotech Celltrion "drops" late-stage Rituxan biosim. Can you imagine this happening w/ a s. molecule? Nope. Report | Follow @RyanMFierce

> Abbott aids biotech Epizyme in matching epigenetic drug with cancer patients. More

> Roche sees another Rituxan biosimilar trial bite the dust. Article

> Antibiotics upstart Allecra snags €15M VC round amid superbug scare. More

Vaccines News

> H7N9 cases jump, some show resistance to Roche's Tamiflu. More

> Polio eradication push nearing endgame again. Story

> ITS eyes Big Pharma suitors as universal flu vaccine advances. Article

> India's Biological E pentavalent vaccine takes on GSK, J&J. Item

> Vaccine campaign struggling to contain measles outbreak. More

Pharma Manufacturing News

> Issues with contractor leads to shortage of GSK's Horizant. More

> Sanofi expands in Morocco with €20M hub. News

> Canada's Pharmascience opens new distribution center. Story

> Hikma will keep injectables manufacturing. More

> Contaminated capsules dissolve Biostar earnings. Article

And Finally... Fame and achievement in performance-related careers may be earned at the cost of a shorter life, a study found. Report

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.